Complete baseline evaluations: This may include blood work and a full metabolic review
The N-terminus has an Aib (2-aminoisobutyric acid) residue, which increases its resistance to enzyme degradation
Some patients with mild gastroparesis tolerate low-dose GLP-1 therapy
The least-squares mean percentage change in body weight from baseline was -7.2% in the 1 mg group, -12.9% in the 4 mg group (starting at 2 mg), -17.1% in the combined 4 mg groups, -17.5% in the combined 8 mg groups, and -17.5% in the 12 mg group, compared with -1.6% in the placebo group
Glutathione, GSH, Glutathione-SH31 [2] 5 mMGSSG, Glutathione-S-S-Glutathione [3] 0.510 mM1/1001/1000 (GSH) (glutathione disulfide, GSSG)298%GSH [] (L--glutamyl-L-cysteinyl-glycine)---- [] 2 2 [] 1NADPH: GSSG + 2 e 2 GSH: 240 mV [4] ) S-(S-)S- (H2O2)(S-)S- 2 -()2 [] -S- (GSTs) I II D- [] [] -2---- [] --- [] --2- [5] [] [] 2016 (RCT) 2RCT1 [6] [] (5-) () [7] [] (phorone) (glutathione depletor) [8] [9] [10] 10201488 [11] [] [] Merck Index , 11th Edition, 4369
Avoiding high-fat foods is particularly important, as dietary fat further delays gastric emptying beyond the medication's effect
